Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria

Nikolaus Pfisterer · Caroline Schmidbauer · Florian Riedl · Andreas Maieron · Vanessa Stadlbauer · Barbara Hennlich · Remy Schwarzer · Andreas Puespoek · Theresa Bucsics · Maria Effenberger · Simona Bota · Michael Gschwantler · Markus Peck-Radosavljevic · Mattias Mandorfer · Christian Madl · Michael Trauner · Thomas Reiberger

Received: 4 August 2020 / Accepted: 3 November 2020 / Published online: 3 December 2020
© The Author(s) 2020

Summary
Background Portal hypertension (PH) causes severe complications in patients with liver cirrhosis, such as variceal bleeding and ascites; however, data on the knowledge and perceptions on guideline recommendations for the management of varices and the use of albumin is scarce.

Methods We designed two structured surveys on (i) the management of varices and (ii) the use of albumin for Austrian physicians of specialized Gastro-Intestinal (GI) centers. The interviewed physicians were confronted spontaneously and provided ad hoc responses to the questionnaire.

Results In total, 158 surveys were completed. Interestingly, many specialists (30%) would recommend a follow-up gastroscopy after 1 year in patients with compensated cirrhosis without varices (i.e., overtreatment). For small varices, 81.5% would use non-se-
selective beta blockers (NSBB) for primary prophylaxis (PP). For PP in patients with large varices, endoscopic band ligation (EBL) plus NSBB was preferred by 51.4% (i.e., overtreatment). Knowledge on the indication criteria for early TIPS (transjugular intrahepatic portosystemic shunt) was reported by 54.3%, but only 20% could report these criteria correctly. The majority (87.1%) correctly indicated a preference to use NSBB and EBL for secondary prophylaxis (SP).

The majority of participating gastroenterologists reported no restrictions on the use of albumin (89.8%) in their hospitals. Of the interviewed specialists, 63.6% would use albumin in patients with SBP; however, only 11.4% would use the doses recommended by guidelines. The majority of specialists using albumin at the recommended doses for hepatorenal syndrome (HRS-AKI, 86.4%) and for large volume paracentesis (LVP, 73.3%). The individual responses regarding albumin use for infections/sepsis, hypotension, renal impairment, and encephalopathy were heterogeneous.

**Conclusion** The reported management of PH and varices is mostly adherent to guidelines, but endoscopic surveillance in patients without varices is too intense and EBL is overused in the setting of PP. Knowledge on the correct use of early TIPS must be improved among Austrian specialists. Albumin use is widely unrestricted in Austria; however, albumin is often underdosed in established indications.

**Keywords** Survey · Practice · Albumin · Non-selective beta blockers · Transjugular intrahepatic portosystemic shunt

**Introduction**

Portal hypertension (PH) causes severe complications in patients with cirrhosis, including ascites, acute variceal bleeding (AVB), hepatorenal syndrome (HRS-AKI), and spontaneous bacterial peritonitis (SBP) [1–3]. Thus, management of PH requires a systematic approach as well as expert knowledge on the prevention and treatment of PH-associated complications in order to improve patient outcome and quality of life. Adherence to guidelines was associated with improved outcomes [4, 5]. The European Baveno VI guidelines and the Austrian Billroth III consensus provide detailed recommendations for the management of PH to guide physicians in their daily clinical practice [1, 2]. Moreover, the European Association for the Study of the Liver (EASL) issued clinical practice guidelines on the management of ascites and its complications and more recently, decompensated liver cirrhosis [3, 6].

Around 30% of patients with cirrhosis develop esophageal varices and despite improvements in the management of variceal hemorrhage, bleeding-related mortality remains as high as 15–20% [7–11]. Importantly, the rate of rebleeding is up to 60% if no adequate secondary prophylaxis is provided [12]. For primary prophylaxis of variceal bleeding, current international guidelines recommend either nonselective beta blockers (NSBB) or endoscopic band ligation (EBL); however, Austrian guidelines indicate a preference for NSBB [2, 13]. Secondary prophylaxis of variceal rebleeding should be performed by combination treatment (NSBB plus EBL) [2, 13]; however, a retrospective study in Austria showed that up to one third of patients received secondary prophylaxis with EBL alone [14]. Among these, medical conditions representing contraindications to NSBB could explain the lack of NSBB therapy in only 25.8% of cases [14, 15]. Furthermore, more than half of the patients in this bicentric study received EBL plus NSBB in primary prophylaxis, although the current guidelines do not recommend this regimen in this setting [2, 13, 14]. It remained largely unknown why adherence to the guidelines was so low. In addition, recent data indicates underutilization of early transjugular intrahepatic portosystemic shunt (TIPS) in clinical routine, although its benefits are well established [16, 17]. Importantly, there is an ongoing controversy regarding the use of NSBB in patients with refractory ascites with or without spontaneous bacterial peritonitis (SBP) [18–21], which likely impacts on the use of NSBB for bleeding prophylaxis by treating physicians, especially in patients with a history of ascites.

The use of albumin is recommended in several indications related to complications of PH [1, 2]. The EASL clinical practice guidelines and Billroth III consensus guidelines recommend the use of albumin in patients with cirrhosis undergoing a large-volume paracentesis (LVP) to prevent paracentesis-induced circulatory dysfunction (PICD), as well as in patients with SBP or hepatorenal syndrome (HRS-AKI) [1, 2, 22, 23]. In addition to the beneficial effects of albumin on renal perfusion, long-term administration of albumin may improve outcomes in patients with ascites [24, 25]. The use of albumin was reported to reduce systemic inflammation, improve hemodynamics and ameliorate neurological symptoms of hepatic encephalopathy (HE) [26–29]. Furthermore, albumin is also used in critically ill patients for circulatory support and has a well-established safety profile [30]; however, the latter indications in patients with cirrhosis are controversially discussed among experts.

Therefore, we aimed to capture the perceptions regarding the management of PH and the use of albumin among physicians caring for patients with cirrhosis in Austria in comparison with current Billroth III recommendations [2]. The surveys covered both knowledge and adherence to guidelines as well as questions regarding controversial issues.
Methods

We designed two structured surveys which were handed out to physicians of specialized GI centers in Austria, who regularly treat patients with cirrhosis. The physicians were spontaneously interviewed at various national meetings between June 2018 and November 2019. It was assured that they could not check the guidelines before answering the questions.

The first survey (survey-A, see “Supplementary Material”), assessed important aspects regarding prophylaxis and treatment of patients with esophageal varices (EV) in their daily clinical practice. Survey-A consisted of 10 questions about the preferred strategy for screening for varices, primary prophylaxis (PP) of EV, surveillance after EBL, treatment of AVB including early TIPS, and secondary prophylaxis (SP) of EV. The questionnaire included case examples with response options to assess how the physician would use nonselective beta blockers (NSBB) in patients with cirrhosis and portal hypertension.

A second survey (survey-B, see “Supplementary Material”) addressed important aspects regarding access/reimbursement and the usage and dosage of albumin in their daily clinical practice. Survey-B consisted of 9 questions including 4 cases about albumin: indications, dosages and access to albumin at their hospital. Survey-B also included case examples with response options regarding the use of albumin in patients with cirrhosis and paracentesis, AVB, hyponatremia, and SBP.

Responses to questions that did not address controversial issues were categorized in correct, wrong or borderline. Answers close to the correct recommendation (i.e., minor deviations in dosage) according to the current guidelines were classified as borderline [1, 2]. If a question was not answered from a physician, the question was marked as not available (n/a).

Information about the population and urban-rural typology of Austria was collected from www.statistik.at (Statistics Austria) [31, 32].

Statistic

Only descriptive statistics were used and all statistical analyses and illustrations were computed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). The number of respective given answers were expressed as absolute numbers and/or percentages.

Ethics

No patients were involved in this survey, and thus, ethics committee approval was not required.

Fig. 1 Flow chart depicting information on participating doctors. Q Question
**Results**

**Demographic characteristics (Fig. 1 and 2, Table S2 in Supplementary Material)**

In total, 70 physicians completed the survey on management of varices (survey-A) and 88 physicians completed the survey (survey-B) on the use of albumin in Austrian hospitals. Among 158 surveys, 126 (79.7%) were answered by specialists (consultants) while 32 (20.3%) were residents/fellows. Importantly, 105 (66.5%) participants were specialized in gastroenterology and hepatology, while 53 (33.5%) of participants were in training/specialized in internal medicine.

Overall, 40 (25.3%) physicians only reported the state (e.g., Burgenland, Carinthia, etc. . . .) of their workplace. Among the remaining physicians, 91 (57.6%) stated to work in state capitals (e.g., Wien, Linz) and 27 (17.9%) physicians worked in smaller cities (e.g., Melk).

Of the 70 interviewed physicians (survey-A) 6 (8.6%) reported not having access to endoscopic services for the treatment of AVB, whereas 79 of 88 (89.8%) interviewed physicians (survey-B, question 1) reported having unrestricted access to albumin. Only 4 physicians (4.5%) provided a more detailed explanation for restricted use of albumin: Two physicians had to fill in specific request forms to obtain albumin, in one institution albumin is only used in intermediate/intensive care, and one physician reported to have no possibility to use albumin in private practice.

The responses given to each individual question are summarized in Fig. 3a, b and Fig. 4a, b.

**Screening for varices, primary prophylaxis and secondary prophylaxis of AVB (Fig. 3a: questions 1–4 and question 7; Fig. 3c, d)**

In compensated patients without varices and ongoing liver injury, only 7.1% (n=5) recommended the next gastroscopy in 2 years (correct answer). Physicians who recommend the next gastroscopy in 1–2 years, i.e. 7.1% (n=5), were regarded as borderline (see Fig. 3a: question 1).

Concerning question 2, when asked about primary prophylaxis in patients with compensated cirrhosis (Child-Pugh Class A5) and small EV without red spot signs (RSS), 57 (81.5%) physicians stated using non-selective beta blockers (NSBB), such as carvedilol or propranolol as a monotherapy; however, 13 (18.6%) would not start a treatment in this case, which was considered as borderline, since Billroth III recommends NSBB use in these patients. No participant stated to use EBL monotherapy or a combined treatment with NSBB and EBL.

In contrast, regarding question 3, 36 (51.4%) of the surveyed persons would perform combined treatment with NSBB and EBL and one physician would not use NSBB or EBL for primary prophylaxis in a patient with compensated cirrhosis (Child-Pugh Class A6) with big varices and red spots, which is clearly not supported by current guidelines (see Fig. 3c). Of note, only 33 (47.1%) physicians would treat these patients correctly with NSBB or EBL monotherapy.

In patients on NSBB without a bleeding event in the past, 40 (57.1%) of the surveyed persons would perform a surveillance gastroscopy, which is not indicated according to the current guidelines (see Fig. 3a: question 4).

Combined treatment (i.e., NSBB plus EBL) was recommended for secondary prophylaxis of variceal
Fig. 3  Responses given to questions regarding the management of varices and variceal bleeding in survey-A to questions with a strong recommendations by guidelines and b weak recommendations by guidelines. c Responses on the preferred choice for primary bleeding prophylaxis in patients with compensated liver cirrhosis (Child-Pugh Class A6) with large varices and red spot signs. d Responses on the preferred choice for secondary prophylaxis of variceal bleeding. Q question, n/a not answered, n number of surveys, NSBB non-selective beta blockers, TIPS transjugular intrahepatic portosystemic shunt, EBL endoscopic band ligation, AVB acute variceal bleeding, PP primary prophylaxis, SP secondary prophylaxis, CI contraindication

Questions addressing issues with controversial/ limited evidence (Fig. 3b: questions 8–10)

In question 8, we addressed the use of NSBB in patients after the first occurrence of grade 3 ascites and worsening of renal function. We asked how physicians would act if the value of serum creatinine increased from 1.4 mg/dL to 1.8 mg/dL (grade 1 acute kidney injury). Only 27 (38.6%) suggested to switch the NSBB therapy from carvedilol to propranolol, while 43 (61.4%) did not choose this option.

Only 40 (57.1%) physicians would consider TIPS implantation in cases of intolerance to NSBB in secondary prophylaxis, which would have been recommended by current guidelines (see question 9).

In question 10 we asked about NSBB treatment in new onset of SBP and 32 physicians (45.7%) would pause the therapy with NSBB until spontaneous bacterial peritonitis was successfully treated. A long-term discontinuation of NSBB was recommended by 12 (17.1%) physicians and 26 (37.1%) would not interrupt/stop NSBB therapy in this case.

Early-TIPS (Fig. 3a: questions 5 and 6)

In the last two questions of survey-A, we asked about the knowledge of indications for early-TIPS.

In question 5, 38 subjects (54.3%) reported knowing the criteria for early TIPS; however, only 14 (20%) of the physicians listed the inclusion criteria accurately. Incomplete answers (n=24, 34.3%) were considered as borderline.

In question 6 we asked for contraindications for early TIPS implantation. Of the responding physicians 52 (74.3%) correctly stated that new onset of HE at the time of acute variceal bleeding is not a contraindication for early TIPS and 1 physician did not answer this question.
Indications for albumin in patients with cirrhosis (see “Supplementary Material, Table S1”)

Question 2 was an open question asking for indications for albumin substitution in patients with cirrhosis. In 53 (60.2%) cases, physicians reported hepatorenal syndrome (HRS-AKI) to be an indication for albumin treatment. In 32 (36.4%) cases, the answer was hypoalbuminemia, SBP was stated 27 (30.7%) times, after paracentesis 46 (52.3%) times, hyponatremia 5 (5.7%) times, 9 subjects (10.2%) listed severe diarrhea and malabsorption, 3 (3.4%) septic shock with cirrhosis, 3 (3.4%) acute renal failure (AKI), 1 (1.1%) HE, and 1 (1.1%) after AVB: 7 (8%) physicians did not respond to this question (n/a).

Use of albumin in acute kidney injury and hepatorenal syndrome (HRS-AKI) (Fig. 4a: questions 3 and 4)

In question 3, we asked how physicians would act if the value of serum creatinine in a patient would increase from 1.4 mg/dL to 1.8 mg/dL, without an improvement after the withdrawal of diuretics. Less than half of the physicians (n = 40, 45.5%) stated that they would administer albumin and 5 (5.7%) physicians did not answer the question (n/a).

In question 4, 76 (86.4%) of the surveyed persons would use albumin in a dosage with 1 g/kg body weight, max. 100 g/day, to establish the diagnosis of HRS-AKI [2] and 6.8% reported not having easy access to albumin or albumin in a sufficient dosage; however, since they would give albumin in this case, the answer was considered borderline. Only 2 (2.3%) physicians did not recommend albumin for this patient and 4 subjects (4.5%) did not answer this question.

Use of albumin after paracentesis and in spontaneous bacterial peritonitis (Fig. 4a: questions 6A and 6D, Fig. 4a and d)

In question 6A we asked physicians which amount of 20% albumin solution they would administer after a paracentesis of 5l of ascites (i.e., LVP). The majority (n = 65, 73.9%) of the physicians stated to use the correct/recommended dose of 40 g (i.e. 200 mL of 20% albumin). 8 physicians (9.1%) indicated to use a dose of 60 g (i.e. 300 mL of 20% albumin), while 10 (11.4%) physicians would use a lower (20 g, i.e. 100 mL of 20% albumin) or a higher (80 g, i.e. 400 mL of 20% albumin) than recommended dose of albumin for LVP: 5 physicians (5.7%) did not respond to this question (Fig. 4c).

Furthermore, around two thirds of the persons interviewed on question 6D would give albumin in spontaneous bacterial peritonitis. Question, n/a not answered, n number of surveys, n/a not answered, SBP spontaneous bacterial peritonitis, BW body weight, AKI acute kidney injury, HRS hepatorenal syndrome.
patients with SBP (63.6% vs. 34.1%, 2.3% n/a). Asking for the albumin dosage in patients with SBP, there was considerable disagreement. Only 14 (15.9%) physicians answered the correct dosage according to the guidelines, while 42 (47.7%) physicians answered close to the current recommendation and were classified as borderline.

**Use of albumin in patients with infections/septic shock and cirrhosis (Fig. 4b: question 5)**

There exists evidence on the use of albumin in patients with cirrhosis and non-SBP infections or septic shock. In question 5, 20.5% (n = 18) would administer albumin in patients with non-SBP infections/septic shock and cirrhosis. Administering albumin in case of hypoalbuminemia was mentioned by 31 physicians (35.2%), while 37 (42%) physicians would administer crystalloid solutions or other non-albumin-based colloids.

**Special case: use of albumin in newly developed hepatic encephalopathy (Fig. 4b: question 6B)**

In question 6B (see “Supplement S2 survey-B”), 26 (29.5%) of the 88 interviewed persons would administer albumin after AVB with newly developed HE.

**Special case: Use of albumin in patients with cirrhosis and hyponatremia (Fig. 4b: question 6C)**

The participants’ opinions regarding the use of albumin in patients with hyponatremia were divergent in question 6C. A large proportion of physicians answered not to use albumin in this situation (47.7%, n = 42 vs. 48.9%, n = 43, 3.4% n/a).

**Discussion**

PH is a leading cause of hospitalization due to complications, such as variceal bleeding and ascites and causes significant morbidity and mortality in patients with cirrhosis which is also evident for Austria [14, 21, 33–36]. Therefore, an adequate prophylaxis and therapy of PH-related complication is crucial. National and international guidelines provide evidence-based recommendations regarding the management of PH [2, 13]; however, there are limited data on the actual knowledge on these recommendations and adherence to current guidelines for PH in daily clinical practice. The results of this survey indicate that many PH guideline recommendations are widely known and followed, while some recommendations are either not known or not followed in real-life [4, 5, 37, 38].

There is no strong recommendation for the use of NSBBs for primary prophylaxis in patients with small varices, since there is only a low bleeding risk [35, 39, 40]; however, a meta-analysis indicated that NSBB treatment for small varices may slow down the progression to large varices [41]. The recent PREDESCI study suggested that patients with small varices indeed benefit from NSBB therapy due to a significant risk reduction for hepatic decompensation and also for mortality [42]. In our survey, most physicians (81.5%) would start NSBB for primary prophylaxis in patients with small varices, which may reflect knowledge on the Austrian recommendations to use NSBB even for small varices. Notably, several studies have demonstrated NSBB-related benefits that are likely mediated by their additional nonhemodynamic effects [14, 18, 43].

Interestingly, many physicians (51.4%) preferred a combined treatment with NSBB plus EBL for primary bleeding prophylaxis in patients with large varices. This approach, however, represents an overtreatment, which increases the risk for severe adverse events, such as EBL-related ulcer bleeding, without being associated with a clear benefit [1, 14, 44–46]. According to current guidelines, in primary prophylaxis either nonselective beta blockers (NSBBs) or endoscopic band ligation is recommended, especially in medium to large varices [2, 13, 23].

The vast majority (81.5%) of the responding physicians in our survey would prefer carvedilol over propranolol for primary prophylaxis, which is likely related to the knowledge on the Austrian carvedilol studies showing superior reductions in portal pressure with carvedilol [36, 47]. Concerning secondary prophylaxis of variceal bleeding, the majority (87.1%) used guideline-conform combination treatment with NSBB plus EBL. In a similar Canadian survey 70.9% of physicians stated to use NSBB plus EBL for secondary prophylaxis [38].

If no varices were found in patients with compensated cirrhosis, many physicians (30%) would recommend a follow-up gastroscopy already after 1 year, which is not supported by current guidelines. The recommended endoscopic screening interval of 2 years was only followed by 7.1%, while another 7.1% stated to perform the next gastroscopy in 1–2 years. This overtreatment by short endoscopic screening intervals causes unnecessary costs and risks for the patients. Importantly, transient elastography may be used as a valuable noninvasive prescreening tool for esophageal varices when combined with a concomitant determination of the platelet count [48, 49]; however, gastroscopy is still considered important in patients with PH, especially in patients who never had gastroscopy before [2], since additional findings such as portal hypertensive gastropathy may be detected as a relevant cause of upper gastrointestinal bleeding and anemia [50–52]. Furthermore, longer screening intervals could be considered in patients with cured hepatitis C, as sustained viral response results in a profound decrease of portal pressure [53, 54].

More than a half of the responding physicians (57.1%) would perform follow-up gastroscopy in pa-
tients on primary prophylaxis with good tolerance and adequate hepatic venous pressure gradient (HVPG)-
response to NSBB, which again would represent an
unnecessary overtreatment not aligned with current
guidelines [1, 2]. Increased knowledge of and adher-
ence to the PH management recommendations could
thus spare resources and reduce costs.

One third of physicians (38.6%) would switch
bleeding prophylaxis from carvedilol to propranolol
in patients with new onset ascites and rising serum
creatinine values. Due to additional vasodilating ef-
effects of carvedilol, the specific safety of carvedilol (but
also of traditional NSBB) in decompensated cirrhosis
is still controversially debated [21, 35, 64–68]. Thus,
this approach seems pathophysiologically reasonable;
however, there is still limited evidence supporting this
switching strategy from carvedilol to propranolol in
patients with ascites and/or renal impairment [35].
Still, the Austrian [2] and European (EASL) [3] re-
commendations state that carvedilol should not be used
in patient with severe ascites. In a similar survey,
which was conducted in Denmark, 33% of the physi-
cians stated not to stop NSBB in patients with renal
impairment and 36% did not consider NSBB therapy
a contraindication in patients with refractory ascites
[37].

Evidence regarding the use of NSBB in patients
with SBP or acute kidney injury is conflicting [35, 39,
55–57]. In our cohort, 37.1% of physicians would not
stop NSBB therapy in patients with SBP. In a similar
Danish survey approximately 50% of clinicians would
not stop NSBB in patients with SBP [37]. Since re-
cent data suggest that continuing NSBB during SBP
is not associated with increased mortality as long as
there is no severe arterial hypotension [58], the
reported perceptions on how to use NSBB therapy
during SBP seems to be mostly in line with current
recommendations.

Knowledge on the indication criteria for early-TIPS
was reported in 54.3%, but only 20% of the respon-
dents could report these criteria correctly. This is
alarming, since several trials [17, 59, 60] including an
Austrian study [59, 61] have demonstrated that early-
TIPS decreases not only the risk of rebleeding but also
mortality in high-risk patients with variceal bleeding
with a number needed to treat of 4.

Furthermore, a lack of systematic use of early-TIPS
in patients with refractory variceal bleeding requir-
ing self-expandable esophageal metal stent implanta-
tion was also evident from another Austrian study [62].
A French survey indicated similar results with only 7%
of eligible patients actually receiving early-TIPS [16].
Finally, a European multicenter study found a consid-
erable underutilization of early-TIPS, although its use
was linked to a survival benefit [63].

Most responses indicated unrestricted access to the
use of albumin in patients with cirrhosis in Austria.
While the established indications for albumin for IVP,
SBP and HRS were almost universally correctly indi-
cated, the reported dosing of albumin was often not
adherent to the recommendations. Specifically, while
63% of physicians would administer albumin in pa-
patients with SBP, only 15.9% indicated to use the rec-
ommended dose in SBP. In a large French study, 94%
of the physicians used albumin for treatment of SBP,
but only 56.2% used the recommended doses of albu-
min [69]. In contrast, the majority of specialists
(73.9%) use the correct dose of albumin in patients
undergoing IVP with 8 g per liter of ascitic fluid re-
moved [1, 2].

We also included questions regarding the use of
albumin in non-established indications in the setting
of cirrhosis, and about one third of physicians indi-
cated to administer albumin in AVB and for hepatic
encephalopathy. As many as 47.7% of physicians
would use albumin for treatment of hyponatremia
in cirrhosis, but only 20.5% would administer albu-
min to cirrhotic patients with non-SBP infections/
septic shock. These responses are relevant, since
recent studies have suggested beneficial albumin-
related immunomodulatory and anti-inflammatory
effects, detoxification functions, and amelioration of
endothelial dysfunction in patients with cirrhosis [26,
70–74].

The spontaneous completion of the survey did not
allow physicians to look up the correct answers to the
questions and thus, represents a major strength of this
study. Since this spontaneous survey most likely re-
deflects true clinical practice in Austria, the actual level
of knowledge on PH management and the use of albu-
mim and the extent recommendations are followed in
real-life can be sufficiently estimated. Unfortunately,
we did not record how many physicians refused to
answer the survey; however, the survey was well-per-
ceived and answered by almost all approached physi-
cians. Furthermore, to overcome the potential bias
related to only asking physicians attending meetings
and training courses who may be better trained than
the average gastroenterologist and hepatologist, we
also directly visited hospitals to ask residents, fellows,
and specialists for internal medicine or gastroenterol-
y and hepatology to fill out the questionnaires.

Although there is generally a good knowledge on
the management of portal hypertension and use of
albumin, there are also areas in which reported prac-
tice deviated from the national evidence-based rec-
ommendations. We think that non-adherence to rec-
ommendations should be detected in every institu-
tion that regularly treats patients with liver cirrhosis
(as would be highly feasible by short questionnaires
as used in this study). This would potentially allow
exploring the reasons for nonadherence to the rec-
nommendations for PH management and for the use
and dosing of albumin in more detail. Subsequently,
specific education on particular aspects of portal hy-
pertension can be organized in order to refresh the
guideline knowledge and optimize patient manage-
ment.
In conclusion, the reported management of PH and varices is mostly adherent to guidelines, but endoscopic surveillance in patients without varices is too intense and EBL is overused in the setting of PP. Knowledge on the correct use of early-TIPS must be improved among Austrian specialists. Albumin use is widely unrestricted in Austria; however, albumin is often underdosed in established indications.

Acknowledgements We thank Stefan Klotzer for legal advice and Irina Gessl and Lukas Unger for proofreading.

Funding Open access funding provided by Medical University of Vienna.

Conflict of interest N. Pfisterer received travel support from Abbvie and MSD. M. Mandorfer has served as a speaker and/or consultant and/or advisory board member for Abbvie, Bristol-Myers Squibb, Gilead, Janssen and W.L. Gore & Associates and has received a research award from Medis. C. Schmid-bauer received travel support von Gebro, Gilead und Abbvie. M. Peck-Radosavljevic has served as a speaker for CSL Behring. T. Reiberger received travel support from Boehringer-Ingelheim, W.L. Gore & Associates, Gilead, Roche and MSD; grant support from Abbvie, Boehringer-Ingelheim, Gilead, W.L. Gore & Associates, Phexen Pharmaceuticals and Phillips; served on advisory boards for Abbvie, Bayer, Boehringer-Ingelheim, Gilead and MSD; and received lecture fees from Boehringer-Ingelheim, Gore, MSD and Roche. All authors declare that they have no conflicts of interests in regard to this study.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.

2. Reiberger T, Páspök A, Schoder M, et al. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III). Wien Klin Wochenschr. 2017;129:135–58.

3. European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406–60.

4. Moodley J, Lopez R, Carey W. Compliance with practice guidelines and risk of a first esophageal variceal hemorrhage in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8:703–8.

5. Loy V, Kwiat J, Dodda A, Martin E, Dua A, Saedian K. Performance feedback improves compliance with quality measures. Am J Med Qual. 2016;31:118–24.

6. Periculous M, Sarnowski A, Moure A, Fijten B, Zaman M. The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Eur J Gastroenterol Hepatol. 2016;28:e10–8.

7. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–9.

8. D’Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599–612.

9. Fairath V, Rehal S, Logan R, Kahan B, Herrnhaw S, Stanworth S, et al. Acute variceal haemorrhage in the United Kingdom: patient characteristics, management and outcomes in a nationwide audit. Dig Liver Dis. 2014;46:419–26.

10. Cerqueira RM, Andrade L, Correia MR, Fernandes CD, Manso MC. Risk factors for in-hospital mortality in cirrhotic patients with oesophageal variceal bleeding. Eur J Gastroenterol Hepatol. 2012;24:551–7.

11. Stokkeland K, Brandt L, Ekomb A, Hultcrantz R. Improved prognosis for patients hospitalized with esophageal varices in Sweden 1969–2002. Hepatology. 2006;43:500–5.

12. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology. 1981;80:800–8.

13. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol. 2005;43:167–76.

14. Pfisterer N, Dexheimer C, Fuchs E-M, et al. Betablockers do not increase efficacy of band ligation in primary prophylaxis but they improve survival in secondary prophylaxis of variceal bleeding. Aliment Pharmacol Ther. 2018;47:966–79.

15. Pfisterer N, Mandorfer M, Reiberger T. Editorial: use of beta-blockers and band ligation in preventing first and recurrent variceal bleeding—“real life” vs evidence-based decisions. Authors’ reply. Aliment Pharmacol Ther. 2018;47:1224–5.

16. Thabut D, Pauwels A, Carbonnell N, et al. Cirrhotic patients with portal hypertension-related bleeding and an indication for early-TIPS: a multivariate study of a real-life results. J Hepatol. 2017;68:73–81.

17. García-Pagán JC, Safio S, Mandorfer M, García-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEPRep. 2020;2:100122.

18. Krag A, Wiest R, Albillos A, Glud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61:967–79.

19. Krag A, Madsen BS. To block, or not to block in advanced cirrhosis and ascites: that is the question. Gut. 2015;64:1015–7.

20. Leithhead JA, Rajoriya N, Tehani A, Hodgson J, Gunson BK, Tripathi D, et al. Non-selective β-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut. 2015;64:1111–9.

21. Mandorfer M, Bota S, Schwabl P, et al. Non-selective β-blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014;146:1680–1690.e1.

22. Runyon BA, AASLD. Introduction to the revised American association for the study of liver diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–3.
the American association for the study of liver diseases. Hepatology. 2017;65:310–35.
24. Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet. 2018;391:2417–29.
25. García-Martínez R, Noiret L, Sen S, Mookerjee R, Jalan R. Albumin infusion improves renal blood flow autoregulation in patients with acute decompensation of cirrhosis and acute kidney injury. Liver Int. 2015;35:335–43.
26. García-Martínez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R. Albumin: pathophysiological basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013;58:1836–46.
27. Martín-Llahí M, Pépin M-N, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008;134:1352–9.
28. Guevara M, Tera C, Nazar A, Solá E, Fernández J, Pavesi M, et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. J Hepatol. 2012;57:759–65.
29. Fernández J, Clària J, Amorós A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with compensated cirrhosis. Gastroenterology. 2019;157:149–62.
30. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.
31. Statistik Austria. Volkszähungen, Registerzählung, Abgestimmte Erwerbsstatistik. 2020. https://www.statistik.at/web_de/statistiken/menschen_und_gesellschaft/bevoelkerung/volkszaehlungen_registerzaehlungen_abgestimmt.html. Accessed 25 Oct 2020.
32. Statistik Austria. Gliederungen nach städtischen und ländlichen Gebieten. 2020. https://www.statistik.at/web_de/klassifikationen/regionale_gliederungen/stadt_land/index.html. Accessed 25 Oct 2020.
33. Bucsics T, Schoder M, Diermayr M, et al. Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding—a two decades experience. PLoS ONE. 2018;13:e0189414.
34. Scheiner B, Parada-Rodriguez D, Bucsics T, et al. Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scand J Gastroenterol. 2017;52:1–8.
35. Reiberger T, Madorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2017;66:849–59.
36. Schwarzar R, Kivarovic D, Paternoster R, Madorfer M, Reiberger T, Trauner M, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. Aliment Pharmacol Ther. 2018;47:1162–9.
37. Thorhauge KH, Lindvig KP, Laleman W, Angeli P, Singh SP, Krag A. Lack of consensus for usage of β-blockers in end-stage liver disease. Gut. 2016;65:1058–60.
38. Cheung J, Wong W, Zandieh I, Leung Y, Lee SS, Ramji A, et al. Acute management and secondary prophylaxis of esophageal varical bleeding: a western Canadian survey. Can J Gastroenterol. 2006;20:531–4.
39. Madorfer M, Reiberger T. Beta-blockers and cirrhosis. 2016. Dig Liver Dis. 2017;49:3–10.
40. Sarin SK, Mishra SR, Sharma P, Sharma BC, Kumar A. Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial. Hepatol Int. 2013;7:248–56.
41. Madorfer M, Peck-Radosavljevic M, Reiberger T. Prevention of progression from small to large varices: are we there yet? An updated meta-analysis. Gut. 2017;66:1347–9.
42. Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDISEC): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019;393:1597–608.
43. Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective beta-blocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58:911–21.
44. Sinclair M, Vaughan R, Angus PW, Gow PJ, Parker E, Hey P, et al. Risk factors for band-induced ulcer bleeding after prophylactic and therapeutic endoscopic variceal band ligation. Eur J Gastroenterol Hepatol. 2015;27:928–32.
45. Sarin SK, Wadhawan M, Agarwal SR, Tyagi P, Sharma BC. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol. 2005;100:797–804.
46. Lo G-H, Chen W-C, Wang H-M, Lee C-C. Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. Hepatology. 2010;52:230–7.
47. Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–41.
48. Madorfer M, Hernández-Gea V, García-Pagán JC, Reiberger T. Noninvasive diagnostics for portal hypertension: a comprehensive review. Semin Liver Dis. 2020; https://doi.org/10.1055/s-0040-1708806.
49. Reiberger T, Ferlitsch A, Payer BA, Pinter M, Schwabl P, Stift J, et al. Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. Wien Klin Wochenschr. 2012;124:395–402.
50. Simbrunner B, Beer A, Wöran K, et al. Portal hypertensive gastropathy is associated with iron deficiency anaemia. Wien Klin Wochenschr. 2020;132:1–11.
51. Scheiner B, Semmler G, Maurer F, et al. Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver Int. 2020;40:194–204.
52. Ripoll C, García-Tsao G. The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis. 2011;43:345–51.
53. Madorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65:692–9.
54. Schwabl P, Madorfer M, Steiner S, et al. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139–49.
55. Giannelli V, Roux O, Laoëtanan C, et al. Impact of cardiac function, refractory ascites and beta-blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol. 2020;72:463–71.
56. Alvarado-Tapias E, Ardevol A, García-Guix M, et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.03.048.
57. Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C, et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol. 2020; https://doi.org/10.1016/j.jhep.2020.05.011.
blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019;50:696–706.

59. Bucsics T, Schoder M, Mandorfer M, et al. Effectiveness of “early” TIPS implantation versus “late” TIPS versus standard endoscopic treatment for acute variceal bleeding in patients with liver cirrhosis. J Hepatol. 2018;68:S694–S5.

60. García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362:2370–7.

61. Bucsics T, Schoder M, Goeschl N, et al. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Dig Liver Dis. 2017;49:1360–7.

62. Pfisterer N, Riedl F, Pachofszky T, et al. Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding—a national multicentre study. Liver Int. 2019;39:290–8.

63. Hernández-Gea V, Procopet B, Giráldez A, et al. Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study. Hepatology. 2019;69:282–93.

64. Sersté T, Melot C, Francoz C, Durand F, Rautou P-E, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017–22.

65. Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40–6.

66. Kalambokis GN, Baltayiannis G, Christou L, Christodoulou D. Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use. Gut. 2016;65:1228–30.

67. Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gastroenterology. 2016;151:1393–4.

68. Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol. 2016;64:574–82.

69. Garidou A, Cadranel J-F, Pauwels A, et al. Albumin use in patients with cirrhosis in France: results of the “ALBU-LIVE” survey: a case for better EASL guidelines diffusion and/or revision. J Clin Gastroenterol. 2017;51:831–8.

70. Spinella R, Sawhney R, Jalan R. Albumin in chronic liver disease: structure, functions and therapeutic implications. Hepatol Int. 2016;10:124–32.

71. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272–84.

72. Stamler JS, Jaraki O, Osborne J, Simon DJ, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA. 1992;89:7674–7.

73. O’Brien AJ, Fullerton JN, Massey KA, et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat Med. 2014;20:518–23.

74. Anraku M, Chuang VFG, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta. 2013;1830:5465–72.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.